View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 18, 2022

Enlivex receives approval for Phase I/II solid tumour trial in Israel

Progression-free survival, overall response rate, and overall survival comprise the key secondary endpoints of the trial.

Enlivex Therapeutics has received approval from the Israeli Ministry of Health (MOH) to commence the Phase I/II clinical trial of Allocetra as a monotherapy, and along with a PD1 checkpoint inhibitor, in advanced solid tumour patients.

Sponsored by the company, the open-label, multicentre, dose-escalation trial will analyse the safety, tolerability, and initial efficacy of Allocetra alone and in combination with a PD1 agent.

It is anticipated to enrol up to 48 subjects in two study stages. 

The trial’s Stage 1 will assess escalating doses of Allocetra given intravenously (IV) or intraperitoneally (IP) weekly for three successive weeks. 

Escalating doses of IV or IP Allocetra, along with anti-PD1 therapy, will be analysed in Stage 2.

Subjects in this stage will be given three doses of Allocetra along with the anti-PD1 agent. 

Assessing the safety and tolerability along the treatment duration and through one week following the last dose of Allocetra is the trial’s primary objective.

Efficacy evaluations such as progression-free survival, overall response rate, and overall survival comprise the key secondary endpoints. 

As an exploratory endpoint, variations in immune cell/cytokine profiling in the peritoneal fluid will be analysed.

Being developed as a universal, off-the-shelf cell therapy, Allocetra could potentially reprogramme macrophages into their homeostatic state. 

Enlivex Medical vice-president Einat Galamidi said: “With Allocetra treatment, we aim to change the balance of macrophage populations surrounding the solid tumour environment in favour of anti-cancer activity, in order to overcome the biological mechanisms underlying checkpoint inhibitor resistance. 

“Collaborative studies with Yale Cancer Center have generated meaningful preclinical data, suggesting we may be successful in these efforts, with Allocetra and an anti-PD1 agent synergistically combining, which delivered a statistically significant survival benefit in a murine model of ovarian cancer.”

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena